Beata Paulina Rurarz

Mrs. Beata Paulina Rurarz

Institute of Applied Radiation Chemistry, Lodz University of Technology, Lodz, Poland
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2016 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
Ruchi BansalRuchi Bansal
Ruchi Bansal
Beata Paulina RurarzBeata Paulina Rurarz
Beata Paulina Rurarz
Jai PrakashJai Prakash
Jai Prakash
Hepatic fibrosis, characterized by excessive accumulation of extracellular matrix (ECM) proteins leading to liver dysfunction, is a growing cause of mortality worldwide. Hepatocellular damage owing to liver injury leads to the release of profibrotic factors from infiltrating inflammatory cells that results in the activation of hepatic stellate cells (HSCs). Upon activation, HSCs undergo characteristic morphological and functional changes and are transformed into proliferative and contractile ECM-producing myofibroblasts. Over recent years, a number of therapeutic strategies have been developed to inhibit hepatocyte apoptosis, inflammatory responses, and HSCs proliferation and activation. Preclinical studies have yielded numerous targets for the development of antifibrotic therapies, some of which have entered clinical trials and showed improved therapeutic efficacy and desirable safety profiles. Furthermore, advancements have been made in the development of noninvasive markers and techniques for the accurate disease assessment and therapy responses. Here, we focus on the clinical developments attained in the field of targeted antifibrotics for the treatment of liver fibrosis, for example, small molecule drugs, antibodies, and targeted drug conjugate. We further briefly highlight different noninvasive diagnostic technologies and will provide an overview about different therapeutic targets, clinical trials, endpoints, and translational efforts that have been made to halt or reverse the progression of liver fibrosis.

1 April 2019 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Open access
Beata Paulina RurarzBeata Paulina Rurarz
Beata Paulina Rurarz
DMDeby F. Mardhian
Deby F. Mardhian
RBRichell Booijink
Richell Booijink
GSGert Storm
Gert Storm
Jai PrakashJai Prakash
Jai Prakash
Ruchi BansalRuchi Bansal
Ruchi Bansal
Hepatic cirrhosis is a growing health problem with increasing mortality worldwide. So far, there is a lack of early diagnosis and no clinical therapy is approved for the treatment. In this study, we developed a novel theranostic nanomedicine by targeting relaxin (RLX) that is known to possess potent anti-fibrotic properties but simultaneously has poor pharmacokinetics and detrimental off-target effects. We conjugated RLX to PEGylated superparamagnetic iron-oxide nanoparticles (RLX-SPIONs) and examined hepatic stellate cells (HSCs) specific binding/uptake. Thereafter, we assessed the therapeutic efficacy of RLX-SPIONs on human HSCs in vitro and in vivo in CCl4-induced liver cirrhosis mouse model. RLX-SPIONs showed specific binding and uptake in TGFβ-activated HSCs, and inhibited TGFβ-induced HSCs differentiation, migration and contraction. In vivo, RLX-SPIONs strongly attenuated cirrhosis and showed enhanced contrast in MR imaging. Altogether, this study presents RLX-SPIONs as a novel theranostic nanomedicine that provides new opportunities for the diagnosis and treatment of liver cirrhosis.

11 August 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MMMalgorzata Matusiak
Malgorzata Matusiak
Beata Paulina RurarzBeata Paulina Rurarz
Beata Paulina Rurarz
Slawomir KadlubowskiSlawomir Kadlubowski
Slawomir Kadlubowski
MWMarian Wolszczak
Marian Wolszczak
UKUrszula Karczmarczyk
Urszula Karczmarczyk
PUPiotr Ulanski
Piotr Ulanski
Radiation crosslinking was employed to obtain nanocarriers based on poly(acrylic acid)—PAA—for targeted delivery of radioactive isotopes. These nanocarriers are internally crosslinked hydrophilic macromolecules—nanogels—bearing carboxylic groups to facilitate functionalization. PAA nanogels were conjugated with an engineered bombesin-derivative—oligopeptide combined with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate chelating moiety, aimed to provide selective radioligand transport. 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium (DMTMM) toluene-4-sulfonate was used as the coupling agent. After tests on a model amine—p-toluidine—both commercial and home-synthesized DOTA-bombesin were successfully coupled to the nanogels and the obtained products were characterized. The radiolabeling efficiency of nanocarriers with 177Lu, was chromatographically tested. The results provide a proof of concept for the synthesis of radiation-synthesized nanogel-based radioisotope nanocarriers for theranostic applications.

Verified
Journal Article
Open access
PDF file
Beata Paulina RurarzBeata Paulina Rurarz
Beata Paulina Rurarz
MBMałgorzata Bukowczyk
Małgorzata Bukowczyk
Natalia Weronika GibkaNatalia Weronika Gibka
Natalia Weronika Gibka
APAgnieszka Piastowska-Ciesielska
Agnieszka Piastowska-Ciesielska
UKUrszula Karczmarczyk
Urszula Karczmarczyk
PUPiotr Ulanski
Piotr Ulanski
Advances in nanomedicine bring the attention of researchers to the molecular targets that can play a major role in the development of novel therapeutic and diagnostic modalities for cancer management. The choice of a proper molecular target can decide the efficacy of the treatment and endorse the personalized medicine approach. Gastrin-releasing peptide receptor (GRPR) is a G-protein-coupled membrane receptor, well known to be overexpressed in numerous malignancies including pancreatic, prostate, breast, lung, colon, cervical, and gastrointestinal cancers. Therefore, many research groups express a deep interest in targeting GRPR with their nanoformulations. A broad spectrum of the GRPR ligands has been described in the literature, which allows tuning of the properties of the final formulation, particularly in the field of the ligand affinity to the receptor and internalization possibilities. Hereby, the recent advances in the field of applications of various nanoplatforms that are able to reach the GRPR-expressing cells are reviewed.

29 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Beata Paulina RurarzBeata Paulina Rurarz
Beata Paulina Rurarz
Kinga Anna UrbanekKinga Anna Urbanek
Kinga Anna Urbanek
UKUrszula Karczmarczyk
Urszula Karczmarczyk
JRJoanna Raczkowska
Joanna Raczkowska
DHDominika Habrowska-Górczyńska
Dominika Habrowska-Górczyńska
PUPiotr Ulanski
Piotr Ulanski
Despite the tremendous development of oncology, prostate cancer remains a debilitating malignancy. One of the most promising approaches to addressing this issue is to exploit the advancements of nanomedicine in combination with well-established nuclear medicine and radiotherapy. Following this idea, we have developed a radioisotope nanocarrier platform of electron-beam-synthesized nanogels based on poly(acrylic acid). We have developed a functionalization protocol, showing the very high (>97%) efficiency of the conjugation in targeting a ligand–bombesin derivative. This engineered peptide can bind gastrin-releasing peptide receptors overexpressed in prostate cancer cells; moreover, it bears a radioisotope-chelating moiety. Our nanoplatform exhibits very promising performance in vitro; the radiolabeled nanocarriers maintained high radiochemical purity of >90% in both the labeling buffer and human serum for up to 14 days. The application of the targeted nanocarrier allowed also effective and specific uptake in PC-3 prostate cancer cells, up to almost 30% after 4 h, which is a statistically significant improvement in comparison to carrier-free radiolabeled peptides. Although our system requires further studies for more promising results in vivo, our study represents a vital advancement in radionanomedicine—one of many steps that will lead to effective therapy for castration-resistant prostate cancer.

25 November 2021 in Nukleonika
Verified
Journal Article
Open access
PDF file
Beata Paulina RurarzBeata Paulina Rurarz
Beata Paulina Rurarz
Natalia Weronika GibkaNatalia Weronika Gibka
Natalia Weronika Gibka
MBMałgorzata Bukowczyk
Małgorzata Bukowczyk
SKSławomir Kadłubowski
Sławomir Kadłubowski
PUPiotr Ulanski
Piotr Ulanski
Synthesis of polymer nanogels (NGs) for biomedical applications is considered to be a very promising application in radiation engineering. Under high-dose pulse irradiation of dilute aqueous polymer solution, reactive species generated by water radiolysis can create multiple radicals on each macromolecule and consequently induce intramolecular cross-linking of polymer chains, resulting in NG formation. The obtained products are free from harmful monomers, initiators, and cross-linking agents, which makes them potentially applicable for drug delivery applications. One of the biggest challenges in handling and use of nanoparticles, however, is the colloidal stability, when aqueous suspensions are stored for prolonged periods. Therefore, development of the best protocols for the particular nanocarrier storage is key. To address this need, we have performed the prospective study in which we systematically assessed the influence of various processing and storage scenarios feasible in our lab, on the colloidal stability of the radiation-synthesized poly(acrylic acid) (PAA) NG particles in suspension. This allowed us to choose the optimal way of handling the product after its synthesis. We confirmed that none of the strategies we used and tested are substantially detrimental to our product. Filtration with 0.2-μm filters was proven sufficient for sample purification and prolonged storage in aqueous suspension did not exert a negative effect on the colloidal stability of particles suspension. We have also demonstrated that lyoprotectant-free lyophilization was suitable for our polymer nanoparticles. This is an important fact for further application of particles as nanocarriers for biologically active compounds such as targeting ligands or therapeutic moieties.